Spine surgery firm SMAIO's H1 sales rise on US expansion

SMAIO SA

16/07/2026 16:54

Overview
France-U.S. spine surgery firm's H1 sales rose 3% to €5.1 mln, topping €5 mln for first time
U.S. sales up 10% in dollars, but euro growth limited by currency and surgeon absence
Company expanded U.S. network with 5 new centers and 13 new surgeons in H1

Outlook
Company to continue expanding U.S. network and partnerships in H2 2026
SMAIO to invest in R&D to enhance and differentiate its product portfolio
Company expects gradual resumption of sales at new U.S. hospital center from July

Result Drivers
SURGEON RELOCATION - Temporary absence of a top U.S. surgeon after moving hospitals led to lower sales in Q2 and H1, with impact expected to fade as procedures resume
NETWORK EXPANSION - Addition of 5 new U.S. centers and 13 new surgeons performing first procedures contributed to revenue growth
CURRENCY IMPACT - Unfavorable euro/dollar exchange rate reduced reported euro growth in U.S. sales

Company press release: ID:nBw75krhma

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Sales
 
EUR 5.1 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for SMAIO SA is €8.30, about 4.4% below its July 15 closing price of €8.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)